Dr David Kallend trained in medicine at King’s College London and King’s College Hospital, qualifying with an MBBS from the University of London in 1988. Following this he trained in surgery, predominantly at the Royal Postgraduate Medical School in London where his final post was as a Research Fellow in the Department of Surgery. During this time his research interests were mainly the use of imaging modalities for diagnosis of surgical conditions. In 1995 he left medical practice and joined Schering AG in Berlin where he spent 3 years working on MRI diagnostics of soft tissue tumors and the vascular system. In 1998 he joined Zeneca where he worked on the development of rosuvastatin from early Phase II into Phase IV. In this post he was initially involved in the phase III program and regulatory activities. Later, as Lead Rest of World Brand Physician he was involved in designing and overseeing many of the Galaxy studies as well as working on the regulatory and marketing strategy for the life cycle of rosuvastatin. In 2005 he moved to Switzerland to work for Roche and for the last 6 years has been the Global Clinical Leader for the development of dalcetrapib, a CETP modulator currently in late stage development. In this role he is a key player in developing the strategy for the development of dalcetrapib and is involved in regular Regulatory Authority interactions globally.
Biography Updated on 13 May 2013